---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-003322"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2021-11-08T23:59:59+00:00"
generated_at: "2026-06-28T11:33:22.107706+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Caribou Biosciences appoints Dara Richardson-Heron to board and Ruhi Khan as Chief Business Officer

## Summary
- Dara Richardson-Heron, M.D., appointed as Class III director effective Nov 4, 2021, and to Nominating Committee.
- Ruhi Khan appointed as Chief Business Officer, bringing 20+ years of biotech business development experience.
- Board size increased from six to seven directors to accommodate Richardson-Heron's appointment.
- Richardson-Heron receives standard director compensation: $40K/yr cash plus $4K/yr for committee; initial option for 44,000 shares vesting over 3 years.

## SEC filing metadata
- accession: 0000950170-21-003322
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2021-11-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000095017021003322/0000950170-21-003322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000095017021003322/crbu-20211104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-003322
- JSON: https://secwatch.observer/filing/0000950170-21-003322.json
- Plain text: https://secwatch.observer/filing/0000950170-21-003322.txt

## Key facts
- Executive change
  Dara Richardson-Heron was appointed as Class III Director at Caribou Biosciences, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: On November 4, 2021, the Board of Directors (the “Board”) of Caribou Biosciences, Inc., a Delaware corporation (the “Company”), increased the size of the Board from six to seven directors and unanimously agreed to extend an offer to Dara Richardson-Heron, M.D., to serve as a Class III director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1619856/000095017021003322/0000950170-21-003322-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.